Testing DSL101, an mRNA treatment, in adults with Wilson disease
Tests DSL101 given by infusion in adults with Wilson disease.
Key facts
- Who runs it
- DSciLab Co., Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- A Clinical Study on the Treatment of Wilson Disease With ATP7B mRNA/LNP (DSL101)
- Status
- Recruiting
- Phase
- Early phase 1
- People taking part
- 18 people, planned
- Started
- 31 Dec 2025
- Expected to end
- Apr 2029
- Type of study
- Interventional, 3 groups
- Treatments tested
- Group 1: DSL101 Low dose
- Group 2: DSL101 Medium dose
- Group 3: DSL101 High dose
- Record updated
- 20 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Wilson's disease that is well controlled on standard treatment. They will get DSL101 as infusions into a vein.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Wilson's disease diagnosed at least one year before screening, with a Leipzig score ≥4. The disease must be stable and well controlled: serum NCC ≥ 25 μg/L and ≤ 150 μg/L, urinary copper ≥100 μg/24 hours and ≤900 μg/24 hours, ALT < 2 times the upper limit of normal.
- Earlier treatment
- At least 6 months of standard treatment (such as D-penicillamine, trientine or zinc) with no drug or dose change for at least 6 months. At least six months of low copper diet before screening. People can keep their usual treatment.
- Biomarker or test result
- Mutations in both copies of the ATP7B gene, confirmed by laboratory tests. Ceruloplasmin level <0.1g/L.
Main reasons for not taking part
- Severe complications of Wilson's disease, such as nerve or mental disorders
- Past liver transplant, other liver disease, or MELD score >13
- Other diseases causing anemia, or nervous system diseases such as Parkinson's disease or epilepsy
- Active hepatitis B or C, or HIV antibody positive
- Pregnant or breastfeeding women
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- Age ≥18 years old, gender not limited
- Meet the diagnostic criteria f Wilson's Disease in "Guidelines for Diagnosis and Treatment of Wilson's Disease (2022 Edition)", with a Leipzig score ≥4, at least one year between diagnosis and screening; ceruloplasmin level <0.1g/L
- Patinets with Wilson's disease confirmed by laboratory tests to have double-chromosome mutations in the ATP7B gene
- Low copper diet for at least six months befoer screening and willing to continue low copper diet during study
- Fertile subjects agreed to adopt reliable contrraceptive methods from the screening until 6 months after the last administration
- The subjects are atable patients with WD who have been trasted for at least six months without drug or dose changes for at least 6 momths at the time of screening , and have continuously used standard treatments [SOC, such as D-penicillamine, sodiu dihydroxypropane sulfonate, dimercaptosuccinic acid, trientine, and zinc preparations (zinc acetate, zinc gluconate, zinc sulfate)] for at least 6 months screening, and allowed subjects to continue with their prior SOC treatment
- The subject's condition was fully controlled after treatment, and its definition must meet all of the following conditions:; Serum NCC level ≥ 25 μg/L and ≤ 150 μg/L; Urinary copper ≥100 μg/24 hours and ≤900 μg/24 hours; ALT < 2 times of upper limit of normal value (ULN); The investigator believes that no other laboratory values or clinical symptoms would stop current standard therapy
- Subjects with good compliance, who can understand and cooperate to complete the requirements of protocol
- The subjects voluntarily participated in the trial and signed the informed consent form
Who cannot take part
- Allergy or intolerance to the investigational drug
- History of gastrointestinal bleeding within six months before screening
- Subjects with history of moderate to severe depression, suicidal thoughts or behaviors and serious psychiatric within 6 months prior to screening
- Subjects who have participated other clinical trial within 3 months prior to screening or plan to participate during the clinical trial
- Wilson's disease is accompanied by severe complications such as neurological and mental disorders
- History of liver transplantation
- Other liver-related diseases and clinical symptoms that can cause liver injury, such as acute and chronic hepatitis, alcoholic liver disease, autoimmune liver disease, drug-induced liver injury, liver cirrhosis, liver ascites, esophageal varices, hepatic encephalopathy, hepatorenal syndrome, liver failure, liver malignancy, etc.; Subjects with Model for end-stage liver disease score (MELD)>13
- Other diseases that can cause hemolysis or anemia, such as erythrocytosis, Mediterranean anemia, hemolytic anemia, various causes of infection, large area burns, etc
- Other diseases that can cause dysfunction of the nervous system, such as Parkinson's disease, Parkinson syndrome, various causes of dystonia, chorea, primary tremor, epilepsy, mental abnormalities (such as history of schizophrenia or suicide attempts), etc
- Subjects who have uncontrolled diseases of thr heart, liver, kidneys, endocrine system, digestive tract, metabolism, blood, or malignant tumors
- Active hepatitis B virus infection or active hepatitis C virus infection, or human immunodeficiency virus antibody positive
- Screening period laboratory examination indicators:; Hemoglobin < 90 g/L; Creatinine clearance ≤30 mL/min, or glomerular filtration rate <45 mL/min/1.73 m²; TBil≥2×ULN,ALP/TBil<4,AST/ALT>2.2; Platelets < 70 ×10\^9/L; Neutrophils < 1.0 × 10\^9 /L
- Pregnant women or lactating women
- Investigators evaluate other subjects who are not suitable to participate in this clinical trial
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study adopted an open, single-arm, non-randomized, dose-escalation research design, aiming to evaluate the safety, tolerability, preliminary efficacy, pharmacokinetic and immunogenicity characteristics of single and multiple intravenous infusions of DSL101 in patients with Wilson's disease.
The 3 groups in the trial
- Group 1: DSL101Treatment being tested
Subjects will receive intravenous infusions of DSL101 once every four weeks.
Treatment: Group 1: DSL101 Low dose
- Group 2: DSL101Treatment being tested
Subjects will receive intravenous infusions of DSL101 once every four weeks.
Treatment: Group 2: DSL101 Medium dose
- Group 3: DSL101Treatment being tested
Subjects will receive intravenous infusions of DSL101 once every four weeks.
Treatment: Group 3: DSL101 High dose
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Clinical Study on the Treatment of Wilson Disease With ATP7B mRNA/LNP (DSL101)
- Plain-language title
- Testing DSL101, an mRNA treatment, in adults with Wilson diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 20 January 2026